Elacytarabine

Drug Profile

Elacytarabine

Alternative Names: CP-4055; ELACYT; UNII-TA7WJG93AR

Latest Information Update: 12 Nov 2013

Price : $50

At a glance

  • Originator Clavis Pharma
  • Developer Aqualis; Clavis Pharma
  • Class Antineoplastics; Arabinonucleosides; Oleic acids; Pyrimidine nucleosides
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute myeloid leukaemia

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Colorectal cancer; Malignant melanoma; Ovarian cancer

Most Recent Events

  • 29 Aug 2013 Discontinued - Phase-II for Acute myeloid leukaemia (combination therapy, early-stage disease, second-line or greater) in France, Germany, Norway and USA (IV)
  • 29 Aug 2013 Discontinued - Phase-III for Acute myeloid leukaemia (late-stage disease) in Australia, Belgium, Canada, France, Germany, Ireland, Italy, Norway, Poland, Romania, Spain, United Kingdom and USA (IV)
  • 01 Apr 2013 Suspended - Phase-II for Acute myeloid leukaemia (combination therapy, second-line therapy or greater, early-stage disease) in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top